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A B S T R A C T
Background: Malaria rapid diagnostic tests (RDTs) are a valid alter-
native to malaria testing with microscopy and are recommended for
the testing of febrile patients before prescribing an antimalarial. There
is a need for interventions to support the uptake of RDTs by health
workers. Objective: To evaluate the cost-effectiveness of introducing
RDTs with basic or enhanced training in health facilities in which
microscopy was available, compared with current practice. Methods:
A three-arm cluster randomized trial was conducted in 46 facilities in
central and northwest Cameroon. Basic training had a practical
session on RDTs and lectures on malaria treatment guidelines.
Enhanced training included small-group activities designed to
change health workers’ practice and reduce the consumption of
antimalarials among test-negative patients. The primary outcome
was the proportion of febrile patients correctly treated: febrile
patients should be tested for malaria, artemisinin combination
therapy should be prescribed for conﬁrmed cases, and no antimalarial
should be prescribed for patients who are test-negative. Individual
patient data were obtained from facility records and an exit
survey. Costs were estimated from a societal perspective using
project reports and patient exit data. The analysis used bivariate
multilevel modeling and adjusted for imbalance in baseline covariates.
Results: Incremental cost per febrile patient correctly treated was $8.40
for the basic arm and $3.71 for the enhanced arm. On scale-up, it was
estimated that RDTs with enhanced training would save $0.75 per
additional febrile patient correctly treated. Conclusions: Introducing
RDTs with enhanced training was more cost-effective than RDTs with
basic training when each was compared with current practice.
Key words: Cameroon, cluster-randomized trial, cost-effectiveness
analysis, health worker training, malaria, practice.
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access article under the CC BY-NC-ND license
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Introduction
In 2010, the World Health Organization updated malaria treat-
ment guidelines to conﬁrm that rapid diagnostic tests (RDTs) are
a valid alternative to testing using microscopy and to recommend
parasitological testing in all patients before prescribing an anti-
malarial [1]. Interest in RDTs has intensiﬁed, and governments
across sub-Saharan Africa are now deciding how to expand
access to malaria testing and whether to introduce RDTs in
health facilities that already offer malaria testing using micro-
scopy. These policy decisions will require revisions to national
malaria treatment guidelines and supporting interventions that
ensure that the policy change is accompanied by a change in
health workers’ practice.
In malaria-endemic areas, cases of uncomplicated malaria are
routinely treated in primary health facilities and hospital out-
patient departments, and clinical guidelines advise that in high-
transmission settings malaria should be suspected in patients
who present with a fever or report having a fever in the past 24
hours [1]. Malaria testing is advised because malaria symptoms
are nonspeciﬁc and the fever may have other causes. Microscopy,
however, requires a laboratory and technicians able to prepare
and read blood slides and these are often limited in low-income
settings. Consequently, it has become common for health workers
to make treatment decisions on the basis of symptoms alone and
for antimalarials to be presumptively prescribed to febrile patients.
RDTs offer considerable potential to transform malaria diag-
nosis and treatment because they do not require a laboratory and
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can be used with minimal training. This potential, however, will
be realized only if health workers prescribe treatment on the
basis of test result. Evidence from several countries, including
Cameroon, suggests that reliance on a presumptive malaria
diagnosis has created a mindset among health workers and
patients that febrile illness should be treated with an antimalarial
and it is not uncommon for antimalarials to be prescribed to
patients who tested negative for malaria [2–6].
The economic argument for introducing RDTs critically
depends on health workers’ practice [7,8]. This assumption has
been emphasized in several studies [7,9,10], and the sensitivity of
cost-effectiveness results to health workers’ practice has been
illustrated using trial data from Tanzania [8]. Results were also
sensitive to the prevalence of malaria in febrile patients, specif-
icity and sensitivity of the test, cost of testing and medicines,
whether nonmalaria febrile illness was a bacterial or self-
resolving viral infection, the efﬁcacy of antimalarials and anti-
biotics taken, and whether patients take medicines as advised [9].
The literature shows that RDTs tend to be more cost-effective
than microscopy when compared with a presumptive diagnosis
[7,11,12], while the cost-effectiveness of RDTs compared with
microscopy depends on the relative cost of the tests, as well as
their speciﬁcity and sensitivity in routine use [10,13–15].
To improve malaria diagnosis and treatment using RDTs in
Cameroon, interventions were designed following formative
research with patients and health workers in two regions of
Cameroon [3,6,16]. The formative research showed that micro-
scopy was available in most of the public and mission facilities
but was underused and less than 50% of the febrile patients were
tested for malaria [6]. Malaria was overdiagnosed: 73% of the
febrile patients received an antimalarial, yet malaria was present
in only 30% of the febrile patients tested by the study team [6].
Moreover, patients often received an antimalarial regardless of
the test result: 82% of the patients who reported that they tested
negative for malaria were prescribed an antimalarial [6]. Qual-
itative research also provided an insight into health workers’
practice and highlighted both a mistrust of malaria test results
and challenges in managing patient expectations [3].
In collaboration with the National Malaria Control Programme
(NMCP) of Cameroon, training modules were developed to sup-
port the introduction of RDTs in public and mission facilities. The
basic training was intended to equip health workers with the
knowledge and practical skills needed to diagnose and treat
uncomplicated malaria, including how to conduct an RDT.
Because improving health workers’ adherence to the malaria
treatment guidelines was a key objective, additional training was
designed that used interactive methods and sought to address
the gap between health workers’ knowledge and practice, and
change prescribing behavior.
This article reports the incremental cost per febrile patient
correctly treated (according to the malaria treatment guidelines)
of each intervention compared with current practice. Cost-
effectiveness was assessed from both a provider perspective
and a societal perspective. The analysis uses statistical methods
suitable for individual patient data on costs and effects obtained
from a cluster randomized trial [17,18].
Methods
Trial Design and Intervention
A cluster randomized trial was designed to evaluate the effective-
ness and cost-effectiveness of introducing RDTs with basic or
enhanced training in facilities in which microscopy was available
compared with current practice. The three-arm cluster random-
ized trial was conducted at 46 public and mission health facilities
that offered malaria microscopy testing and were located in
central and northwest regions of Cameroon where malaria is
endemic. The trial design and interventions are summarized
here, and further details are available elsewhere [19,20]. The trial
was registered (clinicaltrials.gov: NCT01350752), the study proto-
col is available [19], and the main trial article has been published
[20]. The effect of the interventions on the proportion of febrile
patients correctly treated according to the malaria treatment
guidelines was measured by surveying febrile patients exiting
health facilities.
Facilities were stratiﬁed by site, randomly selected, and
allocated to one of three arms: control, basic, and enhanced.
There was no intervention at facilities in the control arm. Each
facility in the two intervention arms was supplied 100 RDTs (SD
Bioline Malaria Ag Pf/Pan, Standard Diagnostics, Yongin, South
Korea) per month without charge. The brand and number of RDTs
supplied was selected on the basis of advice from the NMCP, and
the test is reported to have a minimum detection rate of 97.5% for
Plasmodium falciparum malaria, even at low levels of parasitemia
(200 parasites/ml) [21]. Each facility in the basic arm was invited to
send three health workers to a 1-day training course that was
organized by the study team. The 1-day training had three
lectures on the revised malaria clinical guidelines and a practical
session on how to use RDTs. The enhanced intervention repli-
cated not only the basic intervention but also contained an
additional 2 days of training. The additional training used partic-
ipatory methods to reinforce material covered in the basic training,
while also encouraging health workers to adapt to change, com-
municate effectively, and support each other. For instance, trainers
facilitated small-group work and used problem-solving exercises, a
treatment algorithm game, self-developed participatory drama,
and role-playing. The training courses were delivered by represen-
tatives from the NMCP and members of the study team. Health
workers who attended basic and enhanced training courses were
encouraged to hold training sessions at their facility (hereafter
referred to as in-facility training) and inform their colleagues about
RDTs and the revised malaria treatment guidelines. The trial was
designed to approximate “real-world” rather than controlled con-
ditions, and it was possible, for example, that a facility encountered
stock-outs of RDTs and artemisinin combination therapies (ACTs)
during the evaluation.
Effectiveness of Interventions
The effect of the interventions was measured by the proportion
of febrile patients attending facilities who were correctly treated
according to the revised malaria treatment guidelines. This was a
composite measure that required all febrile patients to be tested
for malaria using microscopy or RDT, patients to receive an ACT
if they have a positive malaria test result, and patients not to
receive an antimalarial if they have a negative malaria test result.
Patients were invited to participate in an exit survey if they
sought treatment for a fever at one of the facilities participating
in the trial, were more than 6 months old, were not pregnant, and
did not have symptoms of severe malaria. With informed con-
sent, the exit survey was administered by trained ﬁeldworkers to
the patient or his or her caregiver. A copy of the malaria test
register in each facility was also obtained. Data collection took
place between October and December 2011 and commenced 3
months after interventions were implemented. The effectiveness
results have been submitted for peer-reviewed publication in an
academic journal [20].
Cost Measurement and Valuation
Health care cost for each patient in the exit survey was estimated
taking into account direct and indirect costs incurred by the
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patient and caregivers to obtain care, net costs to the facility
(adjusting for user fees), and the intervention cost. All costs
were estimated in 2011 in Central African francs (CFA)
and converted to US dollars (US $) at 2011 prices, using a
conversion rate of US $1 ¼ CFA 471.87 (the ofﬁcial exchange rate
for 2011; http://wdi.worldbank.org/table/4.16 [Accessed August
23, 2013]).
Intervention cost
Financial and economic costs of the training interventions were
estimated from project reports and interviews with staff, using
an ingredients-based approach (see Table 3 and Appendix A
found at http://dx.doi.org/10.1016/j.jval.2014.07.010). Start-up
costs were incurred to develop the training materials and to
engage national and local stakeholders in the training program
and revisions to the malaria treatment guidelines. One-off
implementation costs were incurred to train the trainers, admin-
ister and implement the training workshops, and hold in-facility
training. The base-case scenario assumed that one-off imple-
mentation costs would be incurred annually. Many activities to
prepare for basic and enhanced training were conducted simul-
taneously, and the cost that corresponds to each arm has been
determined by estimating which costs would have been incurred
if the interventions were independent. The cost of the in-facility
training was estimated separately for each facility on the basis of
the length of the training and the number of health workers
attending. RDTs were not included in the cost of the intervention
but were captured elsewhere.
The total annual economic cost of the intervention was
estimated for each facility. Start-up costs of the training inter-
ventions were annualized over 4 years using a 3% discount rate
on the basis of the assumption that the training materials would
remain relevant for a minimum of 4 years [22]. The economic
costing also incorporated the time health workers spent at the in-
facility training, for which there was no ﬁnancial cost. The cost of
the intervention per febrile patient was estimated by apportion-
ing the total annual economic cost across all febrile patients who
attend the facility each year on the basis of an estimate obtained
from facility records.
Cost of febrile illness
Costs incurred by patients to diagnose and treat febrile illness
were estimated for each individual participating in the exit
survey, and the mean cost per febrile patient was calculated.
Exit survey respondents described the care received during the
facility visit and reported direct costs incurred for the consulta-
tion, tests undertaken and medicines received, direct cost of
travel and other out-of-pocket expenses, and the time spent at
the facility and for travel. The time of patients and caregivers was
valued at the wage of an unskilled worker (CFA 1200/d).
The costs incurred by facilities to diagnose and treat each
febrile patient were also estimated. The facility cost was esti-
mated for each febrile patient using patient-reported information
on the consultation, such as the cadre of health worker, malaria
tests conducted (by microscopy or RDT), and medicines pre-
scribed and dispensed. These data were combined with detailed
unit cost data collected at selected facilities on the average health
worker time and resource use per activity plus portion of over-
head costs. The net facility cost per febrile patient was estimated
by deducting the amount paid by the patient. In some cases, the
amount paid by the patient exceeded the cost to the facility (i.e.,
net facility cost was zero), though in other cases (often when the
patient was younger than 5 years) the cost to the facility
exceeded the fees paid.
Cost-Effectiveness Analysis
Incremental cost-effectiveness ratios (ICERs) for basic and
enhanced interventions, with each intervention compared with
control, were calculated for the primary outcome (correctly
treated according to guidelines) in an intention-to-treat analysis
from both a provider perspective and a societal perspective. The
ICERs represent the incremental cost for each additional febrile
patient correctly treated.
The cost-effectiveness analysis used individual patient-level
data on costs and effects from the cluster randomized trial
according to the latest methods [17,18,23]. An initial examination
of the data found a correlation between costs and effects at the
individual level and the cluster level and an intracluster correla-
tion in both costs and effects. In addition, although random-
ization of clusters to trial arms should negate the need to include
individual-level and cluster-level covariates, there was imbalance
in selected baseline characteristics across the three arms. The
incremental costs and effects were estimated using a bivariate
multilevel model with covariates. This method simultaneously
estimates the multilevel model for cost, cij, and the multilevel
model for effect, eij:
cij¼ βc0þ βc1ajþ βc2xijþβc3zjþucj þεcij
εcij
εeij
 !
 BVN 0
0
 
,
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eij¼ βe0þ βe1ajþ βe2xijþβe3zjþuej þεeij
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where aj is the arm of the trial, xij are the individual-level
covariates, zj are the cluster-level covariates, β1, β2, and β3 are
the corresponding parameter for these variables, β0 is the con-
stant, and eij and uj capture the individual-level and cluster-level
variation. The assumption of normality was investigated for costs
and effects. The distribution of costs was close to a normal
distribution. We assumed a normal distribution for effects having
considered the alternative speciﬁcations, and having conﬁrmed
that the predicted probabilities from the linear probability model
lay within the 0 to 1 interval, and were similar to those from a
logit model [24,25]. Statistical analysis was completed by running
MLwiN 2.28 from Stata 12.1 [26].
Conﬁdence intervals for the ICERs cannot be interpreted
because there were some observations with worse outcomes
and higher costs and some with better outcomes and lower
costs, and hence these are not reported. Cost-effectiveness
acceptability curves (CEACs) were generated by bootstrapping
the residuals from the bivariate multilevel model with covariates
[17,27]. The CEACs illustrate the probability that each interven-
tion was optimal for a range of willingness-to-pay values, where
the willingness to pay is the value placed on an additional person
treated according to the malaria treatment guidelines [28].
The base-case analysis estimated the cost-effectiveness of the
interventions compared with current practice as implemented for
the trial. The base case included all start-up costs and imple-
mentation costs, assuming that the training materials would
remain useful for 4 years and the training would be held
annually. The cost-effectiveness of the interventions was also
considered in a “scale-up scenario” in which the start-up costs
were excluded because they were a sunk cost, and it was
assumed that the training would be held every 2 years. These
estimates should be useful for the Cameroon government in
deciding whether to scale-up the introduction of RDTs with
health worker training.
Ethics Statement
Ethical approval was obtained from the ethics committees of the
London School of Hygiene and Tropical Medicine (No. 5429) and
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Cameroon National Ethics Committee (No. 030/CNE/DNM/09).
Administrative clearance was obtained from the Ministry of
Public Health (No. D30-343/AAR/MINSANTE/SG/DROS/CRC/JA).
The trial is registered with clinicaltrials.gov (NCT01350752).
Results
The study took place between June and December 2011, and 46
facilities participated in the study. The basic and enhanced
training was successfully delivered to 37 facilities in the inter-
vention arms, and in-facility training was held in 34 facilities (15
of 18 in the basic arm and all 19 in the enhanced arm) (see
Appendix A found at http://dx.doi.org/10.1016/j.jval.2014.07.010).
The implementation and ﬁdelity of the interventions have been
described elsewhere [20].
Study Population
The effectiveness and cost-effectiveness of basic and enhanced
interventions were evaluated using 3982 eligible patients who
completed the exit survey (Table 1). Patient characteristics across
the three arms of the trial show some differences in the age
distribution of patients, and in the proportion that had previously
sought treatment and asked for a blood test. Similarly, although
facilities were randomly allocated to the trial arm, there were
some differences across the arms in the type of facility, the
average number of febrile patients per day, and the percentage of
facilities that encountered stock-outs of ACT in the past
4 weeks.
Effects
The proportion of febrile patients who were correctly treated
according to the clinical guidelines was 42% in the basic arm and
55% in the enhanced arm, compared with 37% in the control arm
(Table 2). This is a composite indicator that requires febrile
patients to be tested for malaria and for their treatment to be
consistent with the malaria test result. Breaking down this
indicator shows that the difference between the arms is largely
in the treatment prescribed and received by patients who tested
negative for malaria: 47% of the patients in the basic arm and 68%
in the enhanced arm were correctly treated compared with 14%
in the control arm. There were also some differences in malaria
positivity rates across the arms, and the percentage of patients
with a positive result was higher when patients were tested using
microscopy rather than RDT. It should be noted that all these
results are unadjusted, and do not take into account the cluster-
ing or the imbalance in the baseline covariates, and more
detailed analyses are presented elsewhere [20].
Costs
The ﬁnancial cost of the basic training was $28,392, and the
ﬁnancial cost of the enhanced training was $63,127. A description
of the resources used is provided in Appendix A found at http://
dx.doi.org/10.1016/j.jval.2014.07.010. The start-up costs constitute
a large proportion of the total ﬁnancial costs (73% and 74% of the
basic and enhanced interventions, respectively), which largely
reﬂects the amount of time staff spent designing, piloting, and
reﬁning the training materials.
On the assumption that the training materials would remain
useful for 4 years, the total annual economic cost was $14,481 for
the basic training and $30,976 for the enhanced training (Table 3).
Table 1 – Patient and facility characteristics.
Characteristic Current practice
(N ¼ 681)
Basic
(N ¼ 1632)
Enhanced
(N ¼ 1669)
Patient’s sex
Male 45.8 45.0 44.0
Female 54.2 55.0 56.0
Patient’s age
6–12 mo 5.7 7.7 6.8
1–4 y 28.9 29.1 29.8%
5–19 y 28.5 22.7 22.1
20–39 y 19.2 26.4 26.2
40þ y 17.3 14.2 15.2
Previously sought treatment for this illness episode
Yes 73.1 59.5 64.8
No 26.9 40.5 35.2
Patient or caregiver asked for a blood test
Yes 36.7 22.4 21.3
No 63.3 77.7 78.7
Type of facility
Public 85.3 61.3 56.7
Mission 14.7 38.7 43.3
Average number of patients at facility per day
Mean (range) 20.5 (5–80) 45.1 (6–300) 51.3 (4–200)
Facility had stock-outs of artemisinin combination therapy in past 4 wk
Yes 14.8 12.3 6.0
No 85.2 87.7 94.0
Study site
Bamenda, northwest region 58.7 42.8 46.6
Yaoundé, central region 41.3 57.2 53.4
Note. Values are % except where indicated.
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The annual economic cost of the training workshops held by
the NMCP and the study team (including the training of
facilitators) was $5497 for two basic workshops that trained 50
health workers from 18 facilities and was $12,100 for two
enhanced workshops that trained 48 health workers from 19
facilities. The economic cost of the in-facility training was on
average $190 per facility in the basic arm and $328 per facility in
the enhanced arm, and included the value of in-kind items and
time of participating health workers. It was estimated that the
total annual economic cost of the training interventions in a
scale-up scenario would be $4662 for basic and $9585 for
enhanced training.
Table 2 – Summary of effects.*
Effect Current practice
(N ¼ 681)
Basic
(N ¼ 1632)
Enhanced
(N ¼ 1669)
Primary outcome
% of febrile patients who were correctly treated according to malaria guidelines 36.8 42.0 55.0
Components of primary outcome
% tested for malaria 79.2 76.6 78.6
If malaria test-positive, % with ACT 75.6 74.3 75.8
If malaria test-negative, % without an antimalarial 13.7 46.6 68.2
Malaria test type and result†
If tested for malaria, % tested using microscopy 100 63.4 57.3
% positive if tested using microscopy 53.2 39.7 46.0
% negative if tested using microscopy 45.9 60.3 54.0
If tested for malaria, % tested using RDT – 36.6 42.7
% positive if tested using RDT – 23.2 30.6
% negative if tested using RDT – 76.9 69.4
Treatment prescribed or received
Of those not tested N ¼ 274 N ¼ 385 N ¼ 479
% with any antimalarial 90.4 62.1 55.3
% with an ACT 75.6 48.3 47.8
% with an antibiotic 69.6 56.4 52.8
Of those who tested positive for malaria N ¼ 235 N ¼ 773 N ¼ 730
% with any antimalarial 96.7 92.5 94.4
% with an ACT 75.6 74.3 75.8
% with an antibiotic 39.1 44.9 42.6
Of those who tested negative for malaria N ¼ 135 N ¼ 351 N ¼ 320
% with any antimalarial 86.3 53.4 31.8
% with an ACT 81.3 41.9 22.9
% with an antibiotic 71.5 62.5 63.4
ACT, artemisinin combination therapy; RDT, rapid diagnostic test.
* The results are unadjusted and do not take into account the clustering or the imbalance in baseline covariates across the study arms.
† From facility records. Across the three arms, 144 patients were retested by the study team, with 92 patients previously tested using
microscopy and 52 tested using RDT. Of the 92 patients previously tested using microscopy, we found that 18 (20%) were true positive, 51
(55%) were true negative, 22 (24%) were false positive, and 1 (1%) was false negative. Of the 52 patients previously tested using RDT, we found
that 10 (19%) were true positive, 37 (71%) were true negative, 4 (8%) were false positive, and 1 (2%) was false negative.
Table 3 – Financial and economic costs of the basic and enhanced training (US $, 2011 prices).
Financial cost*
Annual economic cost
Financial cost Base case† Scale up‡
Base case Basic Enhanced Basic Enhanced Basic Enhanced
Start-up
Develop training (including stakeholder engagement) 20,670 46,970 5,561 12,636 0 0
Training workshop
Train facilitators and hold workshops 5,497 12,100 5,497 12,100 2,873 6,324
In-facility training
Health workers train colleagues 2,225 4,057 3,423 6,240 1,789 3,261
Total cost 28,392 63,127 14,481 30,976 4,662 9,585
* Financial costs incurred to design and implement training.
† Start-up costs are treated as investment and annualized over 4 y. Assumes health workers are trained annually. Cost of in-facility training
takes into account in-kind items and health workers’ time
‡ Excludes start-up costs. Assumes health workers are trained every 2 y; thus, implementation costs are treated as investment and annualized
over 2 y. Cost of in-facility training takes into account in-kind items and health workers’ time.
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The mean cost per febrile patient was estimated from both
the provider and societal perspectives, and presented by study
arm for both the base-case and scale-up scenarios (Table 4). The
mean cost of training per febrile patient in the base-case scenario
was $0.52 in the basic arm and $1.12 in the enhanced arm (and
falls to $0.16 and $0.35, respectively, for the scale-up scenario). In
the base-case scenario, the total cost per febrile patient in the
base-case scenario was $1.28 in the basic arm and $1.88 in the
enhanced arm from a provider perspective and $13.47 in the basic
arm and $13.69 in the enhanced arm from a societal perspective.
The substantial difference between provider and societal costs
arises because patients pay user fees to access health care, which
vary by facility and depend on the care received. The average out-
of-pocket cost relating to the consultation, tests conducted, and
treatment received was reported to be $8 to $10 per febrile patient.
Cost-Effectiveness
In the base-case scenario, the interventions were not only more
costly but also more effective than current practice. From a provider
perspective, the incremental cost per patient correctly treated was
$10.13 for the basic intervention and $6.70 for the enhanced
intervention (Table 5). From a societal perspective, which includes
any costs incurred by patients, the incremental cost per patient
correctly treated was $8.40 for the basic intervention and $3.71 for
the enhanced intervention. Thus, it was more cost-effective to
introduce RDTs with enhanced training, than basic training, when
each intervention was compared with current practice.
The cost of the intervention is reduced in the scale-up scenario,
and the interventions become more cost-effective. From a provider
perspective, incremental cost per patient correctly treated was
$4.39 for the basic arm and $2.45 for the enhanced arm. From a
societal perspective, incremental cost was $2.46 per patient cor-
rectly treated in the basic arm, while the enhanced arm had a net
saving of $0.75 per additional patient correctly treated.
The probabilities that each intervention was cost-effective at
different levels of the cost-effectiveness threshold compared
with current practice are illustrated using CEACs (Fig. 1). These
graphs show that the basic intervention has the lowest proba-
bility of being cost-effective at all values from both a provider
Table 4 – Mean cost per febrile patient (US $ 2011 prices).
Cost Current practice (N ¼ 681) Basic training (N ¼ 1632) Enhanced training (N ¼ 1669)
Mean (Min, Max) Mean (Min, Max) Mean (Min, Max)
Cost of training*
Base case – – 0.52 (0.04, 1.57) 1.12 (0.11, 5.44)
Scale-up scenario – – 0.16 (0.01, 0.50) 0.35 (0.04, 1.73)
Cost of febrile illness incurred by patients and caregivers†
Consultation† 1.10 (0.00, 16.11) 1.14 (0.00, 12.72) 1.55 (0.00, 8.48)
Microscopy† 3.97 (0.00, 20.13) 4.11 (0.00, 19.50) 3.42 (0.00, 20.13)
RDT† – 3.10 (0.00, 19.50) 2.43 (0.00, 18.65)
Treatment† 3.77 (0.00, 20.66) 4.70 (0.00, 20.98) 4.16 (0.00, 20.98)
Travel† 0.34 (0.00, 12.72) 0.51 (0.00, 10.60) 0.56 (0.00, 10.60)
Other (including food)† 0.20 (0.00, 14.83) 0.32 (0.00, 17.17) 0.23 (0.00, 11.23)
Travel time (return journey)‡ 0.35 (0.00, 2.80) 0.30 (0.00, 4.77) 0.36 (0.00, 9.66)
Time at facility‡ 1.48 (0.04, 11.44) 2.07 (0.00, 6.48) 2.13 (0.00, 36.62)
Total costs to patient 10.49 (0.51, 41.96 12.18 (0.17, 45.99 11.80 (0.08, 41.07)
Cost of febrile illness incurred by the facility§
Consultation 1.51 (0.78, 2.48) 1.60 (0.78, 2.48) 1.56 (0.78, 2.48)
Microscopy (if applicable) 1.38 (1.38, 1.38) 1.38 (1.38, 1.38) 1.38 (1.38, 1.38)
RDT (if applicable) – 1.71 (1.71, 1.71) 1.71 (1.71, 1.71)
Treatment (if received) 2.58 (0.38, 9.92) 2.22 (0.38, 16.91) 2.37 (0.38, 16.17)
Total cost to facility 4.82 (0.88, 12.61) 4.85 (0.78, 21.10) 4.88 (0.78, 19.19)
Net cost to facility|| 0.77 (0.00, 9.11) 0.77 (0.00, 19.65) 0.76 (0.00, 16.86)
Total cost: provider perspective¶
Base case 0.77 (0.00, 9.11) 1.28 (0.04, 20.62) 1.88 (0.11, 18.68)
Scale-up scenario 0.77 (0.00, 9.11) 0.93 (0.01, 19.96) 1.11 (0.04, 17.36)
Total cost: societal perspective#
Base case 11.27 (1.89, 41.96) 13.47 (2.32, 46.40) 13.69 (2.01, 44.21)
Scale-up scenario 11.27 (1.89, 41.96) 13.11 (1.78, 46.12) 12.91 (1.81, 43.05)
HW, health worker; RDT, rapid diagnostic test.
* Total cost of intervention per facility (obtained from project reports and interviews with staff) divided by the number of febrile patients per
facility per year (estimated from facility records).
† From patient exit survey. Patients reported the amount, including zero costs if the category was applicable.
‡ Time of patient (and caregiver if applicable). Amount of time, as reported in exit survey. Time valued at wage of an unskilled worker (Central
African franc 1200/d or US $2.54).
§ From facility costing undertaken at nine facilities. Facility unit cost per activity was estimated taking into account the use of HW time,
equipment, and supplies. Cost to facility per febrile patient was estimated from exit survey data on resource use (e.g., if tested, type of test,
medicines received) and average unit costs from facility costing. Cost per-patient takes into account the cadre of HW (as reported by the
patient) for each activity, where possible.
|| Total cost to facility less amount patient reported for consultation, test, and treatment.
¶ Sum of training cost and net cost to facility.
# Sum of training cost, patient cost, and net cost to facility.
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perspective and a societal perspective. Current practice has the
highest probability of being cost-effective at very low threshold
levels (o$5), though as the threshold increases so does the
probability that the enhanced intervention is cost-effective. The
CEACs for the scale-up scenario lie to the left of the base-case
scenario, and in the scale-up scenario from a societal perspective
the enhanced intervention has the highest probability of being
cost-effective at all threshold values.
Discussion
The cluster randomized trial evaluated the introduction of RDTs
with either basic or enhanced training in health facilities in
which microscopy was available. The interventions had a pos-
itive effect on health workers’ practice in the diagnosis and
treatment of febrile illness, though were also more costly than
current practice. The enhanced intervention was more cost-
effective than the basic intervention when each intervention
was compared with current practice, which indicates that the
additional 2 days of training represent good value for money.
Because there is no established cost-effectiveness threshold in
Cameroon, however, the question of whether it is cost-effective
to introduce RDTs (with training) in health facilities in which
microscopy is already available will depend on the government’s
willingness to pay for improvements in the diagnosis and treat-
ment of febrile patients. The incremental cost of introducing
RDTs with enhanced training for the trial was $3.71 per patient
correctly treated from a societal perspective (2011 prices). Similar
ICERs have been reported elsewhere [7,10,11,13,29]. For instance,
the incremental cost per patient correctly treated by replacing
microscopy with RDTs in public health facilities was $3.6 in
Ghana (2009 prices) [13], $1.78 in low malaria transmission areas
in Uganda, and $8.9 in high malaria transmission areas in
Uganda (2011 prices) [11].
Differences in study design should be noted, however, when
comparing results, and our study was distinctive for several
reasons. First, RDTs were introduced to complement rather than
replace malaria microscopy because existing laboratory services
were expected to continue in Cameroon. Second, we included the
costs of training health workers and distributing revised guide-
lines because the NMCP indicated that changes in policy would
need to be disseminated. The need for interventions that improve
health workers’ adherence to clinical guidelines was also identi-
ﬁed in formative research and highlighted in the cost-
effectiveness literature [3,6,8]. Third, the study used individual
patient-level data collected in a real-world setting, which meant
that the availability, use, and quality of malaria testing was not
controlled and there was variation among febrile patients in
whether they were tested for malaria, the type of test used, the
treatment prescribed, and the prices charged. Finally, the analy-
sis applied statistical methods that took into account the cluster
randomized design, correlation between costs and effects, and
imbalance between arms in baseline characteristics [17,18].
Several aspects of the study design should be noted when
interpreting effectiveness and cost-effectiveness results. The
NMCP considered training as integral to the introduction of RDTs,
and the evaluation was designed to focus on whether health
workers adhered to the malaria treatment guidelines. As a result,
it is not possible to distinguish the effect of introducing RDTs
from the effect of training, though the observed differences
between the basic and enhanced arms suggest that training
alone can change health workers’ practice. Moreover, the study
was not designed to assess the speciﬁcity and sensitivity of the
tests conducted and the primary outcome was measured using
the test result recorded by health workers. Disaggregating this
outcome indicated that there were similar results across the
study arms in the proportion of febrile patients tested for
malaria. This countered our expectations because we had
expected that the interventions would encourage malaria testing
but we also noted that there had been a substantial increase in
the use of testing since 2009 [6].
The decision to focus on the treatment supplied in a single
consultation, rather than the health outcome of the illness
episode, also has limitations for the cost-effectiveness analysis
and it would not have been possible to estimate the number of
deaths (or disability-adjusted life-years) averted without making
several assumptions about the speciﬁcity and sensitivity of each
diagnostic method, causes of nonmalaria febrile illness, patient
adherence to medication, or the costs and effects of subsequent
Table 5 – Incremental costs and effects.*
Cost Basic vs. current
practice
Enhanced vs. current
practice
Incremental effect (difference in % correctly treated) 0.10 (0.03–0.32) 0.25 (0.17–0.47)
Provider perspective
Incremental cost (US $ 2011 prices)
Base case 1.06 (0.67–2.08) 1.67 (1.24–2.74)
Scale-up 0.46 (0.10–1.36) 0.56 (0.22–1.43)
Incremental cost per febrile patient correctly treated (US $ 2011 prices)†
Base case 10.13 6.70
Scale-up 4.39 2.25
Societal perspective
Incremental cost (US $ 2011 prices)
Base case 0.85 (0.12 to 3.62) 0.92 (0.17–3.89)
Scale-up 0.25 (0.77–2.90) 0.19 (1.31 to 2.40)
Incremental cost per febrile patient correctly treated (US $ 2011 prices)†
Base case 8.40 3.71
Scale-up 2.46 0.75
ICER, incremental cost-effectiveness ratio.
* Estimates from bivariate multilevel model, having adjusted for clustering, correlation between costs and effects, and imbalance in baseline
characteristics.
† Conﬁdence intervals for the ICERs were not reported because there were some observations with worse outcomes and higher costs and some
with better outcomes and lower costs and they cannot be interpreted.
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treatment seeking. There are, however, plans to synthesize ﬁnd-
ings from this and other cost-effectiveness studies undertaken
within the ACT Consortium (www.actconsortium.org), and the
synthesis will include data on the accuracy of microscopy and
RDT in routine use and data from following up febrile patients.
The study was designed to approximate the real world,
though the extent to which this can be achieved in the context
of a trial could be questioned. For example, although the number
and distribution of RDTs supplied was based on advice from the
NMCP and sought to replicate the existing supply management
systems, some modiﬁcations may be needed for nationwide
implementation. The timing of the evaluation is a further con-
sideration. The results reﬂect the situation 3 months postim-
plementation, but we do not know whether the effect of the
interventions on health workers’ practice will be sustained.
We considered a scale-up scenario to facilitate the govern-
ment’s decision on whether to roll out RDTs beyond the study
sites. In this analysis, the start-up costs incurred to develop the
training were considered a sunk cost. Excluding start-up costs not
only substantially reduces the cost of the intervention but also
Fig. 1 – Cost-effectiveness acceptability curves.
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increases the probability that interventions were cost-effective.
Moreover, from a societal perspective, the results indicate that it
would be net saving to introduce RDTs with enhanced training,
though there is uncertainty surrounding the point estimates.
Finally, the ﬁndings highlight two areas for further research.
First, differences in the malaria positivity rates by type of test
should be explored because data from a limited sample of
patients retested by the study team indicated there were more
false positives with microscopy than with RDT. The observed
differences are unlikely to affect the ﬁndings of this study, which
assesses whether the treatment prescribed was consistent with
the test result recorded by the provider; however, it would be
valuable to understand the implications for health outcomes and
the incremental cost-effectiveness of each diagnostic method in
routine use. Second, the patient cost of testing and treatment
warrants further investigation. There was considerable variation
in the cost of malaria diagnosis and treatment and the cost
reported by patients was often high compared with the amount
we estimated it cost health facilities to provide these services. It
will be important to understand the extent to which cost is a
barrier to treatment seeking.
Conclusions
It was more cost-effective to introduce RDTs with enhanced
training than RDTs with basic training when each was compared
with current practice. The supplementary training improved
health workers practice, especially in terms of reducing the
consumption of antimalarials among test-negative patients.
Since the trial concluded, the Cameroon government has revised
the national malaria treatment guidelines to support the use of
RDT and recommend that all febrile patients be tested for malaria
using microscopy or RDT. The NMCP has incorporated the
enhanced training in its efforts to disseminate the policy change
and health worker training commenced in January 2014.
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